12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LMTX: Phase III started

TauRx began a double-blind, placebo-controlled, international Phase III trial to evaluate twice-daily 100 mg oral LMTX for 18 months in about 500 patients with mild AD. LMTX is also in Phase...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >